Valuation: Avacta Group Plc

Market Cap 295M 395M 353M 325M 551M 37.46B 561M 3.88B 1.56B 19.71B 1.48B 1.45B 62.15B P/E 2026 *
-8.77x
P/E 2027 * -14.6x
Enterprise Value 290M 388M 347M 320M 541M 36.83B 551M 3.81B 1.53B 19.37B 1.46B 1.42B 61.1B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.82%
Yield 2026 *
-
Yield 2027 * -
1 day-0.82%
1 week-4.42%
1 month-15.97%
3 months-9.02%
6 months-19.33%
Current year+4.31%
1 week 60
Extreme 60
63
1 month 60
Extreme 60
70
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
152
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Director/Board Member 59 28/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/24 A Sell

Chief Financial Officer

500,000 0.1393%
9/2/24 A Free

Chief Executive Officer

3,600,000 1.0027%
9/2/24 A Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-4.42%-13.57%-57.39% 395M
-0.62%-1.87%+42.87%+67.17% 63.77B
+0.35%+3.20%+14.40%+73.89% 56.37B
+0.53%+1.96%+16.24%+102.20% 54.62B
-2.81%-4.31%+23.50%+48.51% 44.06B
-0.33%-1.93%+19.28%+104.26% 42.11B
+0.55%+2.31%+225.14%+840.10% 41B
+3.27%+47.96%+112.84%+91.02% 34.92B
+1.22%-1.44%+14.57%+47.05% 32.82B
+0.89%+20.55%-40.62%+350.50% 24.7B
Average +0.22%+6.34%+41.46%+166.73% 39.47B
Weighted average by Cap. +0.18%+5.43%+47.93%+173.18%

Financials

2026 *2027 *
Net sales - -
Net income -35.42M -47.45M -42.5M -39.09M -66.2M -4.51B -67.44M -466M -187M -2.37B -178M -174M -7.47B -14.03M -18.79M -16.83M -15.48M -26.22M -1.78B -26.71M -185M -74.11M -939M -70.53M -69.03M -2.96B
Net Debt -4.98M -6.67M -5.97M -5.49M -9.3M -633M -9.48M -65.5M -26.29M -333M -25.02M -24.49M -1.05B 20.79M 27.86M 24.95M 22.95M 38.87M 2.65B 39.6M 274M 110M 1.39B 105M 102M 4.39B
Projected Income Statement - Annual - Avacta Group Plc
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
30/10/26 GBX 60.50 -0.82% 833,122
29/10/26 GBX 61.00 -0.81% 712,499
28/10/26 GBX 61.50 -.--% 805,572
27/10/26 GBX 61.50 -1.60% 2,234,097
26/10/26 GBX 62.50 -1.26% 1,076,397
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Avacta Group Plc
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.6050GBP
Average target price
0.9175GBP
Spread / Average Target
+51.65%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avacta Group Plc
  1. Stock Market
  2. Stocks
  3. AVCT Stock